YU30003A - Inhibicija zavisnosti faktora rasta na ćelije tumora - Google Patents

Inhibicija zavisnosti faktora rasta na ćelije tumora

Info

Publication number
YU30003A
YU30003A YU30003A YUP30003A YU30003A YU 30003 A YU30003 A YU 30003A YU 30003 A YU30003 A YU 30003A YU P30003 A YUP30003 A YU P30003A YU 30003 A YU30003 A YU 30003A
Authority
YU
Yugoslavia
Prior art keywords
inhibition
tumor cells
growth factor
factor dependency
dependency
Prior art date
Application number
YU30003A
Other languages
English (en)
Inventor
Rosemarie Lichtner
Ulrike Fuhrmann
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of YU30003A publication Critical patent/YU30003A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Pronalazak se odnosi na upotrebu inhibitora progesteron receptora za inhibiciju zavisnosti od faktora rasta ćelija tumora.[The invention relates to the use of progesterone receptor inhibitors for inhibition of growth-factor-dependency of tumor cells.
YU30003A 2000-10-18 2001-10-17 Inhibicija zavisnosti faktora rasta na ćelije tumora YU30003A (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24101000P 2000-10-18 2000-10-18
DE10051609A DE10051609A1 (de) 2000-10-18 2000-10-18 Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen

Publications (1)

Publication Number Publication Date
YU30003A true YU30003A (sh) 2006-08-17

Family

ID=7660193

Family Applications (1)

Application Number Title Priority Date Filing Date
YU30003A YU30003A (sh) 2000-10-18 2001-10-17 Inhibicija zavisnosti faktora rasta na ćelije tumora

Country Status (10)

Country Link
US (1) US20040157811A1 (sh)
AR (1) AR034562A1 (sh)
DE (1) DE10051609A1 (sh)
EC (1) ECSP034604A (sh)
PE (1) PE20020472A1 (sh)
PT (1) PT1414465E (sh)
TW (1) TWI234458B (sh)
UY (1) UY26975A1 (sh)
YU (1) YU30003A (sh)
ZA (1) ZA200303785B (sh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
CA2683517A1 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238950A (en) * 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Also Published As

Publication number Publication date
PE20020472A1 (es) 2002-06-15
PT1414465E (pt) 2007-01-31
US20040157811A1 (en) 2004-08-12
ZA200303785B (en) 2005-08-29
DE10051609A1 (de) 2002-05-02
TWI234458B (en) 2005-06-21
UY26975A1 (es) 2002-06-20
AR034562A1 (es) 2004-03-03
ECSP034604A (es) 2003-06-25

Similar Documents

Publication Publication Date Title
HK1071697A1 (en) Inhibition of the growth factor dependency of tumor cells
AU8419201A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
NZ516292A (en) Pyrrolotriazine inhibitors of kinases
NO20005255L (no) Pyrazolpyrimidin-CGMPPDE5-inhibitorer for behandling av seksuell dysfunksjon
HK1076739A1 (en) Use of urease for inhibiting cancer cell growth
EP1009755A4 (en) STEROID SULFATASE INHIBITORS AND METHODS OF PRODUCING AND USING THE SAME
ZA200106197B (en) Use of glycogen phosphorlase inhibitors to inhibit tumor growth.
YU30003A (sh) Inhibicija zavisnosti faktora rasta na ćelije tumora
TW200508233A (en) Chk-1 inhibitors
AU2001277524A1 (en) Novel use of inhibitors of the epidermal growth factor receptor
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
AU2003228450A8 (en) Inhibition of tumor growth via peroxiredoxin 3
AU2002228913A1 (en) Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer
IL139144A0 (en) Mycobacterial inhibitors
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
SI1351958T1 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
WO2004026242A3 (en) Substituted ketophosphonate inhibitors of tumor cell proliferation